Additive effects on cardiac conduction w/ β-blockers or digitalis. Increased exposure of ivabradine (Cmax
, AUC). Increased bioavailability of propranolol. Increased plasma levels and AUC w/ cimetidine. Increased plasma levels of ciclosporin & carbamazepine. Concurrent use w/ erythromycin may cause risk for heart irregularities for those w/ long QT manifestations. Increase AUC of statins. May increase everolimus blood conc. Digoxin, anesth, warfarin, rifampin or lithium.